Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk/Experiment 2
From BugSigDB
Reviewed Marked as Reviewed by Fatima on 2022/07/3
Subjects
- Location of subjects
- United States of America
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Colon Hindgut,Large bowel,Posterior intestine,Colon,colon
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Colorectal cancer cancer of colorectum,cancer of large bowel,cancer of large intestine,cancer of the large bowel,colon cancer,colorectal cancer,colorectum cancer,CRC,large intestine cancer,malignant colorectal neoplasm,malignant colorectal tumor,malignant colorectum neoplasm,malignant large bowel neoplasm,malignant large bowel tumor,malignant large intestine neoplasm,malignant large intestine tumor,malignant neoplasm of colorectum,malignant neoplasm of large bowel,malignant neoplasm of large intestine,malignant neoplasm of the large bowel,malignant neoplasm of the large intestine,malignant tumor of large bowel,malignant tumor of large intestine,malignant tumor of the large bowel,malignant tumor of the large intestine,Colorectal cancer
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Placebo
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Aspirin
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Experimental group took 325 mg daily aspirin over six weeks, with additional six weeks of washout
- Group 0 sample size Number of subjects in the control (unexposed) group
- 20
- Group 1 sample size Number of subjects in the case (exposed) group
- 30
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 3 months
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Statistical test
- Mixed-Effects Regression
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
Signature 1
Reviewed Marked as Reviewed by Fatima on 2022/07/3
Source: Table 4, text
Description: Regression coefficients (β) and P-values for the interaction term comparing the abundance of pre-specified faecal bacterial taxa in aspirin to placebo arm after 3 weeks (upper row) and 6 weeks (lower row) of treatment vs baseline, the ASMIC study
Abundance in Group 1: increased abundance in Aspirin
| NCBI | Quality Control | Links |
|---|---|---|
| Akkermansia | ||
| Lachnospira sp. | ||
| Oscillospiraceae | ||
| Prevotella | ||
| Faecalibacterium |
Signature 2
Reviewed Marked as Reviewed by Fatima on 2022/07/3
Source: Table 4, text
Description: Regression coefficients (β) and P-values for the interaction term comparing the abundance of pre-specified faecal bacterial taxa in aspirin to placebo arm after 3 weeks (upper row) and 6 weeks (lower row) of treatment vs baseline, the ASMIC study
Abundance in Group 1: decreased abundance in Aspirin
| NCBI | Quality Control | Links |
|---|---|---|
| Bacteroides | ||
| Dorea | ||
| Parabacteroides | ||
| Ruminococcus |
